L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension
- 670 Downloads
Neurogenic orthostatic hypotension is a cardinal feature of generalised autonomic failure and commonly is the presenting sign in patients with primary autonomic failure. Orthostatic hypotension can result in considerable morbidity and even mortality and is a major management problem in disorders such as pure autonomic failure, multiple system atrophy and also in Parkinson’s disease. Treatment is ideally two pronged, using non-pharmacological and pharmacological measures.
Drug treatment ideally is aimed at restoring adequate amounts of the neurotransmitter noradrenaline. This often is not achievable because of damage to sympathetic nerve terminals, to autonomic ganglia or to central autonomic networks. An alternative is the use of sympathomimetics (that mimic the effects of noradrenaline, but are not identical to noradrenaline), in addition to other agents that target physiological mechanisms that contribute to blood pressure control.
L-threo-dihydroxyphenyslerine (Droxidopa) is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. It has no pressor effects in this form. It can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline. Experience in Caucasians and in Europe is limited mainly to patients with dopamine beta hydroxylase deficiency. This review focuses on two studies performed in Europe, and provides information on its efficacy, tolerability and safety in patients with pure autonomic failure, multiple system atrophy and Parkinson’s disease. It also addresses the issue of whether addition of dopa decarboxylase inhibitors, when combined with l-dopa in the treatment of the motor deficit in Parkinson’s disease, impairs the pressor efficacy of Droxidopa.
Key wordsl-dihydroxyphenylserine orthostatic hypotension autonomic failure noradrenaline multiple system atrophy Parkinson's disease
Major investigators have included Professor P Cortelli, Professor J M Senard, and many colleagues in participating centres. Disclosure Prof. C.J. Mathias was the Principal Investigator of both studies reviewed, which were supported by Sumitomo Pharmaceuticals, Japan. He is a Consultant for Chelsea Therapeutics, USA.
- 3.Lahrmann H, Cortelli, Hilz M, Mathias CJ, Struhal W, Tassinari M. (2006) European Federation of Neurological Society guidelines on the diagnosis and management of orthostatic hypotension. Europ J Neurol 13:930–6Google Scholar
- 4.Man in’t Veld AJ, Van den Meiracker AH, Boomsma F, Schalekamp MADH. (1987) Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine beta-hydroxylase deficiency. Lancet ii:1172–5Google Scholar
- 5.Mathias CJ, Bannister R, Cortelli P, Heslop K, Polak J, Raimbach SJ, Springall DB, Watson L. (1990) Clinical autonomic and therapeutic observations in two siblings with postural hypotension and sympathetic failure due to an inability to synthesize noradrenaline from dopamine because of a deficiency of dopamine beta-hydroxylase. QJM, New Series 75(278):617–633Google Scholar
- 7.Mathias CJ, Senard J-M, Braune S, Watson L, Aragishi A, Keeling J, Taylor M. (2001) L-threo-dihydroxphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-centre, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Aut Res 11:235–242CrossRefGoogle Scholar
- 8.Mathias CJ, Bannister R. (2002) Dopamine beta-hydroxylase deficiency. In: Mathias CJ, Bannister R, (eds.) Autonomic failure. A textbook of clinical disorders of the autonomic nervous system. 4th ed. Oxford and New York: Oxford University Press pp. 387–401Google Scholar
- 9.Mathias CJ. (2003) Autonomic diseases – clinical features and laboratory evaluation. JNNP 74:31–41Google Scholar
- 10.Mathias CJ. (2003) Autonomic diseases – Management. JNNP 74:42–47Google Scholar
- 11.Mathias CJ. (2005) Cardiovascular Autonomic Dysfunction in Parkinson’s Disease and Parkinsonian Syndromes. In: Ebadi M, Pfeiffer RF. (Eds.) Parkinson’s Disease. CRC Press LLC, New York 295–317Google Scholar
- 12.Mathias CJ. (2006) Orthostatic hypotension and orthostatic intolerance. In: DeGroot LJ, Jameson JL, de Kretser D, Grossman AB, Marshall JC, Melmed S, Potts JT, Weir GC. (Eds.) Endocrinology. 5th edition. Elsevier Saunders, Philadelphia PA, USA 2613–2632Google Scholar
- 13.Mathias CJ, Senard JM, Cortelli P. (2007) A double-blind, randomized, placebo-controlled study to determine the efficacy and safety of droxidopa in the treatment of orthostatic hypotension associated with multiple system atrophy or Parkinson’s disease. Clin Aut Res 17:272. abstractGoogle Scholar
- 14.Narabayashi H, Nakanishi T. (1987) Therapeutic effects of L-DOPS in Parkinson’s disease, double-blind comparative study against placebo as control in patients with long-term levodopa therapy. Clin Eva1 15:423–457Google Scholar
- 16.Sobue I, Senda Y, Hirayama K, et al. (1987) Clinical pharmacological evaluation of L-threo-3-4-dihydroxyphenylserine (L-DOPS) in Shy-Drager’s syndrome and its related diseases. A nationwide double-blind comparative study. Jpn J Clin Exp Med 141:353–378Google Scholar